| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Aug 8, 2019 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 80,000 | $95.31 | $7,624,974.50 | -6.0% | |
| Aug 7, 2019 | AMRX Amneal Pharmaceuticals, Inc. | Boyer Andrew S | Exec VP, Comm Optns | Buy | 66,666 | $2.89 | $192,664.74 | +227.5% | |
| Aug 6, 2019 | BUDZ Weed, Inc. | Kwestel Elliot | Director | Sell | 10,000 | $0.51 | $5,095.00 | -7.8% | |
| Aug 6, 2019 | AMRX Amneal Pharmaceuticals, Inc. | Fosun International Ltd | 10% Owner | Buy | 327,000 | $2.91 | $951,570.00 | New | |
| Aug 5, 2019 | LFCR Lifecore Biomedical, Inc. \de\ | Obus Nelson | Director | Buy | 10,000 | $10.50 | $105,000.00 | +0.4% | |
| Aug 5, 2019 | AMRX Amneal Pharmaceuticals, Inc. | Fosun International Ltd | 10% Owner | Buy | 1,642,300 | $3.04 | $4,992,592.00 | New | |
| Aug 2, 2019 | LFCR Lifecore Biomedical, Inc. \de\ | Obus Nelson | Director | Buy | 20,000 | $10.72 | $214,400.00 | +0.7% | |
| Aug 2, 2019 | RMTI Rockwell Medical, Inc. | Richmond David S. | 10% Owner, See Footnotes 1 And 2 | Buy | 1,904 | $2.65 | $5,041.18 | +1.8% | |
| Aug 1, 2019 | ESPR Esperion Therapeutics, Inc. | Mayleben Timothy M | President &CEO | Buy | 5,000 | $39.56 | $197,800.00 | +7.6% | |
| Jul 31, 2019 | BMY Bristol Myers Squibb Co | Bertolini Robert J | Director | Buy | 11,000 | $44.72 | $491,920.00 | +2,771% | |
| Jul 31, 2019 | CPIX Cumberland Pharmaceuticals Inc | Bernard Gordon R | Director | Sell | 4,872 | $5.82 | $28,369.24 | -1.1% | |
| Jul 30, 2019 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 44,356 | $92.77 | $4,114,857.63 | -13.5% | |
| Jul 30, 2019 | NBIX Neurocrine Biosciences Inc | Lyons Gary A54 | Director | Sell | 10,000 | $92.07 | $920,686.00 | -4.1% | |
| Jul 30, 2019 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 15,831 | $92.13 | $1,458,568.60 | -44.2% | |
| Jul 30, 2019 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 60,000 | $92.92 | $5,575,438.00 | -20.9% | |
| Jul 29, 2019 | RMTI Rockwell Medical, Inc. | Richmond Brothers, Inc. | See Footnotes 1, 2 And 3 | Sell | 179 | $3.12 | $558.48 | -0.1% | |
| Jul 29, 2019 | ANIK Anika Therapeutics, Inc. | Land Raymond J | Director | Sell | 3,000 | $55.44 | $166,320.00 | -20.0% | |
| Jul 26, 2019 | IRWD Ironwood Pharmaceuticals Inc | Gilbert Halley E | Chief Admin Officer &SVP | Sell | 20,000 | $10.00 | $200,000.00 | -7.7% | |
| Jul 25, 2019 | RMTI Rockwell Medical, Inc. | Richmond David S. | 10% Owner, See Footnotes 1 And 2 | Buy | 2,898 | $3.12 | $9,047.94 | +0.7% | |
| Jul 24, 2019 | CPIX Cumberland Pharmaceuticals Inc | Krogulski Kenneth55 | Director | Buy | 1,820 | $6.22 | $11,323.00 | - | |
| Jul 24, 2019 | CPIX Cumberland Pharmaceuticals Inc | Galante Joseph C47 | Director | Buy | 1,680 | $6.23 | $10,463.40 | +0.5% | |
| Jul 24, 2019 | CPIX Cumberland Pharmaceuticals Inc | Kazimi A J59 | Chairman And CEO | Buy | 1,680 | $6.23 | $10,463.40 | - | |
| Jul 23, 2019 | ESPR Esperion Therapeutics, Inc. | Biotech Target N V55 | 10% Owner | Buy | 50,000 | $42.65 | $2,132,565.00 | +1.4% | |
| Jul 22, 2019 | SNY Sanofi | Sanofi | 10% Owner | Buy | 93,750 | $16.00 | $1,500,000.00 | +20.2% | |
| Jul 22, 2019 | RMTI Rockwell Medical, Inc. | Richmond David S. | 10% Owner, See Footnotes 1 And 2 | Buy | 161,457 | $2.95 | $475,881.43 | +234.8% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.